Growth hormone and neurofibromatosis.
| dc.contributor.author | Howell, Simon J | |
| dc.contributor.author | Wilton, Patrick | |
| dc.contributor.author | Lindberg, Anders | |
| dc.contributor.author | Shalet, Stephen M | |
| dc.date.accessioned | 2009-11-19T15:38:34Z | |
| dc.date.available | 2009-11-19T15:38:34Z | |
| dc.date.issued | 2000 | |
| dc.identifier.citation | Growth hormone and neurofibromatosis. 2000, 53 Suppl 1:70-6 Horm. Res. | en |
| dc.identifier.issn | 0301-0163 | |
| dc.identifier.pmid | 10895046 | |
| dc.identifier.doi | 10.1159/000053208 | |
| dc.identifier.uri | http://hdl.handle.net/10541/86502 | |
| dc.description.abstract | Data collected from 102 neurofibromatosis (NF) children with growth hormone (GH) deficiency (GHD) who were receiving GH replacement therapy were reviewed to assess the efficacy and safety of GH therapy in this condition. GH was administered at a mean dose of 0. 18 mg/kg/week. During the 1st year the median height velocity increased significantly from 4.2 cm/year before treatment to 7.1 cm/year, and the median height standard deviation score increased from -2.4 to -1.9. The response to therapy, however, was not as good as that observed in patients with idiopathic GHD. GH therapy did not influence the progression of any of the features of NF, including intracranial tumours, and was not associated with an excess of other adverse events. We conclude that GH treatment of NF patients with GHD is beneficial in terms of improved growth rate and is well tolerated. | |
| dc.language.iso | en | en |
| dc.subject.mesh | Adolescent | |
| dc.subject.mesh | Body Height | |
| dc.subject.mesh | Child | |
| dc.subject.mesh | Child, Preschool | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Human Growth Hormone | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Neurofibromatoses | |
| dc.subject.mesh | Optic Nerve Glioma | |
| dc.subject.mesh | Treatment Outcome | |
| dc.title | Growth hormone and neurofibromatosis. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Endocrinology, Christie Hospital NHS Trust, Manchester, UK. | en |
| dc.identifier.journal | Hormone Research | en |
| html.description.abstract | Data collected from 102 neurofibromatosis (NF) children with growth hormone (GH) deficiency (GHD) who were receiving GH replacement therapy were reviewed to assess the efficacy and safety of GH therapy in this condition. GH was administered at a mean dose of 0. 18 mg/kg/week. During the 1st year the median height velocity increased significantly from 4.2 cm/year before treatment to 7.1 cm/year, and the median height standard deviation score increased from -2.4 to -1.9. The response to therapy, however, was not as good as that observed in patients with idiopathic GHD. GH therapy did not influence the progression of any of the features of NF, including intracranial tumours, and was not associated with an excess of other adverse events. We conclude that GH treatment of NF patients with GHD is beneficial in terms of improved growth rate and is well tolerated. |